UNASSIGNED: 110 Background: @entity5 @entity1 , especially those on chemotherapy, have complex medical histories. They experience a variety of medical problems from their @entity5 and treatments. This quality improvement study is designed to collect information about chemotherapy related @entity341 ( @entity341 ) visits to estimate @entity341 utilization rates, recognize patterns and evaluate other confounders. The goal is to assess and reduce @entity341 use at @entity283 through improved care management. METHODS: The one-year data analysis includes any @entity1 who received chemotherapy in an outpatient care setting and had a visit to the @entity341 within 60 days of treatment. Chemotherapy was defined by designated @entity1191 codes combined with a primary @entity5 diagnosis. Every @entity341 visit was matched to all available chemotherapy visits for each @entity1 , retaining the chemotherapy visit nearest in chronology prior to the @entity341 visit. Data Exclusions: (a) @entity1 who received chemotherapy outside @entity283 , and then accessed an @entity283 @entity341 ; (b) @entity1 who received inpatient chemotherapy. RESULTS: There were 28,738 chemotherapy encounters for 4,264 unique @entity1 system-wide. @entity283 EDs saw 1,669 visits for 1,048 unique @entity1 within 60 days of chemotherapy (24.6%). The top three @entity5 diagnoses were 21% thoracic; 21% GI; and 16% lymph/hematopoietic. Of the 1,669 @entity341 visits, 35% occurred within seven days and 77% within 30 days of treatment. Almost half (45.6%) of the @entity341 visits occurred during normal office hours. No significant variation was noted by day of week. An initial focus was on the tertiary center which represented 318 (20%) of the 1,669 @entity341 visits. The most common diagnoses for an @entity341 visit were @entity158 (17%) and deconditioning (17%), followed by @entity281 (11%) and respiratory symptoms (11%). CONCLUSIONS: This study documents the @entity341 utilization by @entity283 chemotherapy @entity1 . Unexpectedly, @entity341 use occurred frequently during normal office hours. Most visits were represented by a limited number of @entity5 diagnoses and presenting complaints. Intervention is planned to reduce @entity341 use after chemotherapy at @entity283 through improved @entity1 education and by shifting these visits to less expensive venues when possible.

Opportunities for better management of @entity5 in @entity1 receiving chemotherapy at XXXX ( @entity283 ), a large integrated health system in eastern Wisconsin.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity283 :: ('OMIM:603663', 'Disease') :: ['AHC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer'] @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED'] @entity1191 :: ('CHEBI:27656', 'Chemical') :: ['CPT'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain']
@entity283 :: (OMIM:603663,Disease) :: ['Aurora Health Care']
